IL311917A - Methods for Inducing Hemodynamic Change by Administering an Anti-NPR1 Antibody - Google Patents

Methods for Inducing Hemodynamic Change by Administering an Anti-NPR1 Antibody

Info

Publication number
IL311917A
IL311917A IL311917A IL31191724A IL311917A IL 311917 A IL311917 A IL 311917A IL 311917 A IL311917 A IL 311917A IL 31191724 A IL31191724 A IL 31191724A IL 311917 A IL311917 A IL 311917A
Authority
IL
Israel
Prior art keywords
effecting
administering
methods
hemodynamic change
npr1 antibody
Prior art date
Application number
IL311917A
Other languages
English (en)
Hebrew (he)
Inventor
Michael Dunn
Aaron Kithcart
Benjamin Adam Olenchock
Original Assignee
Regeneron Pharma
Michael Dunn
Aaron Kithcart
Benjamin Adam Olenchock
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma, Michael Dunn, Aaron Kithcart, Benjamin Adam Olenchock filed Critical Regeneron Pharma
Publication of IL311917A publication Critical patent/IL311917A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL311917A 2021-10-11 2022-10-11 Methods for Inducing Hemodynamic Change by Administering an Anti-NPR1 Antibody IL311917A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163254447P 2021-10-11 2021-10-11
PCT/US2022/077908 WO2023064769A1 (en) 2021-10-11 2022-10-11 Methods of effecting a hemodynamic change by administering an anti-npr1 antibody

Publications (1)

Publication Number Publication Date
IL311917A true IL311917A (en) 2024-06-01

Family

ID=84045029

Family Applications (1)

Application Number Title Priority Date Filing Date
IL311917A IL311917A (en) 2021-10-11 2022-10-11 Methods for Inducing Hemodynamic Change by Administering an Anti-NPR1 Antibody

Country Status (12)

Country Link
US (2) US20240327539A1 (enExample)
EP (1) EP4415820A1 (enExample)
JP (1) JP2024537284A (enExample)
KR (1) KR20240099275A (enExample)
CN (1) CN118159290A (enExample)
AU (1) AU2022363841A1 (enExample)
CA (1) CA3234238A1 (enExample)
CL (1) CL2024001071A1 (enExample)
CO (1) CO2024005662A2 (enExample)
IL (1) IL311917A (enExample)
MX (1) MX2024004302A (enExample)
WO (1) WO2023064769A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023107957A1 (en) 2021-12-06 2023-06-15 Regeneron Pharmaceuticals, Inc. Antagonist anti-npr1 antibodies and methods of use thereof
AU2024287056A1 (en) * 2023-06-08 2025-12-11 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anti-npr1 antibody and pharmaceutical use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
EP2370098A4 (en) 2008-12-03 2013-07-17 Morphosys Ag Antibodies for guanylyl cyclase receptors
CA3115102A1 (en) 2018-10-23 2020-04-30 Regeneron Pharmaceuticals, Inc. Anti-npr1 antibodies and uses thereof
PH12021553101A1 (en) * 2019-06-12 2023-10-02 Novartis Ag Natriuretic peptide receptor 1 antibodies and methods of use
US12325752B2 (en) * 2020-12-18 2025-06-10 Regeneron Pharmaceuticals, Inc. Immunoglobulin proteins that bind to NPR1 agonists

Also Published As

Publication number Publication date
JP2024537284A (ja) 2024-10-10
CA3234238A1 (en) 2023-04-20
MX2024004302A (es) 2024-06-19
WO2023064769A1 (en) 2023-04-20
KR20240099275A (ko) 2024-06-28
CO2024005662A2 (es) 2024-05-10
AU2022363841A1 (en) 2024-03-28
US20240327539A1 (en) 2024-10-03
EP4415820A1 (en) 2024-08-21
CL2024001071A1 (es) 2024-12-06
US20250034279A1 (en) 2025-01-30
CN118159290A (zh) 2024-06-07

Similar Documents

Publication Publication Date Title
GB201915444D0 (en) Method of using a blockchain
IL288825A (en) Methods for producing anti-alpha4 antibody in cell7
PL3924988T3 (pl) Sposób produkcji korpusu spiralnego ze ściskaniem spirali
IL276075A (en) Glucornylation as a novel post-translational acidic modification on therapeutic monoclonal antibodies
IL286306A (en) Manufacturing methods for producing anti-tnf antibody compositions
IL284789A (en) Immunoglobulin a antibodies and methods of production and use
GB201901576D0 (en) Production of 3C library
IL281079A (en) Production method for a tetracyclic compound
PL3620059T3 (pl) Sposób wytwarzania proszku spożywczego, korzystnie wegańskiego, na bazie mączki migdałowej
GB201902908D0 (en) Method of using a blockchain
IL279528A (en) A method for producing a controlled mixture of two or more different antibodies
EP3978015A4 (en) BISPECIFIC ANTIBODIES
IL285984A (en) Method for producing influenza ha split vaccine
GB202210334D0 (en) Methods of production of aginine-silicate complexes
IL290825A (en) Methods of producing antibody compositions
GB201917525D0 (en) A transducer for producing vibrational movement
ZA202006996B (en) Track part made of a hypereutectoid steel
HK40110421A (en) Methods of effecting a hemodynamic change by administering an anti-npr1 antibody
GB201809783D0 (en) A method of producing a structure
IL290300A (en) Novel composition comprising antibodies
PL3822054T3 (pl) Sposób produkcji płyty fornirowanej
IL283678A (en) Process for preparing bicyclic enolether
IL289210A (en) Method for the production of an antibody
EP3749367A4 (en) USING THE GHR-106 MONOCLONAL ANTIBODY AS A GNRH ANTAGONIST
EP4363455A4 (en) METHOD OF ADMINISTRATION OF ANTI-HPA-1A MONOCLONAL ANTIBODY